Full abstracts will be available on the ASCO website on May 22, 2025, at 5:00 pm ET. Oral Presentation Title: Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma Presenting author: Martin Wermke, MD Session: Developmental Therapeutics – Immunotherapy Date / Time: May 31, 2025 / 3:00 – 6:00 pm CDT Abstract ID: 2508 Poster Presentation Title: SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy ...